Compositions and methods of modulating S-nitrosylation

Inventors

Stamler, Jonathan S.

Assignees

Case Western Reserve University

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12551467-B2

Patent

Publication Date

2026-02-17

Expiration Date


Abstract

A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

Core Innovation

The invention relates to treating cardiovascular disorders by administering an AKR1A1 inhibitor to promote protein S-nitrosylation in the heart of a subject. The method is directed to subjects in need thereof for congestive heart failure (CHF), cardiac hypertrophy, myocardial infarction, myocardial ischemia, myocardial ischemia reperfusion injury, cardiomyopathies, or arrhythmias.

The documented mechanistic background states that AKR1A1 reduces SNO-CoA and metabolizes GSNO, and that AKR1A1 knockout increases protein S-nitrosylation. This increased S-nitrosylation is associated with reduced oxidative stress and protection against myocardial ischemia/reperfusion injury.

The invention further relates to specific AKR1A1 inhibitor embodiments that include SNO-Coenzyme A reductase (SNO-CoAR) inhibitors, in particular imirestat and imirestat analogues. The disclosure includes chemical structure definitions supporting substituent options and related constraints for the imirestat analogue embodiments.

Claims Coverage

The independent claim covers a method of treating one or more listed cardiovascular disorders by administering an AKR1A1 inhibitor at an amount effective to promote S-nitrosylation of proteins in the heart. The independent claim relies on a single core inventive concept (AKR1A1 inhibition to promote cardiac protein S-nitrosylation).

AKR1A1 inhibitor promotes cardiac protein S-nitrosylation for treating cardiovascular disorders

Administering to a subject an AKR1A1 inhibitor at an amount effective to promote S-nitrosylation of proteins in the heart and treat at least one of congestive heart failure (CHF), cardiac hypertrophy, myocardial infarction, myocardial ischemia, myocardial ischemia reperfusion injury, cardiomyopathies, or arrhythmias.

Across the provided independent claim, the inventive coverage centers on administering an AKR1A1 inhibitor to promote S-nitrosylation of proteins in the heart as a treatment for the listed cardiovascular disorders. Dependent claims further refine the AKR1A1 inhibitor identity and properties, including SNO-CoAR inhibitors such as imirestat and imirestat analogues, and specify selectivity and combination aspects versus AKR1B1.

Stated Advantages

Protects against myocardial ischemia/reperfusion injury.

Increases protein S-nitrosylation.

Reduces oxidative stress.

Documented Applications

Treatment of congestive heart failure (CHF).

Treatment of cardiac hypertrophy.

Treatment of myocardial infarction.

Treatment of myocardial ischemia.

Treatment of myocardial ischemia reperfusion injury.

Treatment of cardiomyopathies.

Treatment of arrhythmias.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.